GSK gets rights to Medivir's HIV compounds; ends deal
Executive Summary
GlaxoSmithKline licensed exclusive worldwide rights (excluding certain Nordic countries) to Medivir AB's (develops drug candidates that suppress and regulate protease and polymerase functions) MIV-210, a compound in Phase I development for treating HIV.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice